There is clear evidence that early diagnosis andtreatment of SMAleads to better outcomes. Early detection of the condition is critical; it is particularly important during the current transition towards newborn screening for SMA.

Newborn screening for SMA is beginning to be introduced and evaluated across parts of the UK, but it is not yet available consistently to every baby.
This means that, for the time being, where a baby is born can affect whether they have access to newborn screening for SMA.
We urgently need to help bridge this geographical inequality while newborn screening is being introduced. For babies who have not been screened, recognising possible signs and acting on concerns continues to be an importantroute towards diagnosis.

SPOTSMA Campaign

Phase one of the campaign, developed in partnership with the iHV (Institute of Health Visiting), focuses on empowering healthcare visitors. As trusted professionals who work closely with families in their homes and communities, healthcare visitors are uniquely placed to notice early developmental concerns, build strong relationships, and support families who may face barriers to accessing traditional healthcare services.  

This campaign is funded by Novartis, Biogen and Roche. They had no involvement o influence over the content and development of the campaign or materials. 

E-Learning and Good Practice Points

To access the e-learning module: 

• Follow this link Spinal muscular atrophy: early identification
• Scroll down the page and click on the e-learning graphic
• You now have to make an account by clicking ‘sign up now’ , underneath the log in boxes.
• Input your email and make a new password.
• A code will be sent to your email, do remember to check your junk box.
• Input the code and press enter
• Click enrol me 
• Work through the e-learning!  

Download SpotSMA SMAUK resources here: 

SpotSMA A3 Posters

SpotSMA Leaflet

To order a SpotSMA SMA UK resource pack fill out the form below: